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CHAPTER 1: GENERAL INTRODUCTION 
 
Introduction 
Epileptogenesis is the dynamic alteration of the neuronal excitability in the brain that 
leads to the development of spontaneous recurrent seizures (SRS) (1,2). Epilepsy is characterized 
by SRS and is said to have developed once they occur following an insult to the brain. Brain 
insult is a specific term used for describing the series of pathological injuries to the brain that 
may initiate abnormal changes. These changes can be elicited by mutated genes or acquired brain 
pathology (3). Dynamic alterations pertain to the capacity of neuronal cells to have intrinsic burst 
discharge, disinhibition, or synchronized excitatory synaptic circuitry resulting from the brain 
insults observed in epileptic brains (4). Around 50 million people worldwide have epilepsy, with 
30% of epileptic patients not responding to the current treatments, garnering the name 
“intractable epilepsy” (5). Therefore, discovering the underlying mechanisms of epilepsy has 
become essential to conceive adequate therapies due to the incidence of resistance to the anti-
epileptic drug (AED) (5,6). Temporal lobe epilepsy (TLE) is the most widely studied form of 
epilepsy and is characterized by locally synchronous neuronal firing that spreads throughout the 
brain (6). Many animal models have been created to mimic epilepsy in human to study its 
underlying pathology for potential treatment options. Epilepsy can be the result of various 
conditions such as TBI, stroke, brain tumors, febrile seizures in children (2), along with 
neurodegenerative disorders such as Alzheimer’s disease (7). These conditions have been shown 
to lead to a variety of cellular changes in the brain environment including neurodegeneration, 
reactive gliosis, neurogenesis, mossy fiber sprouting, blood–brain barrier (BBB) impairment, and 
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infiltration of inflammatory cells (2). However, the downstream signaling cascade that may 
result in these changes remains unclear (6).   
In current studies, one of the proposed mechanisms of epileptogenesis involves tau, a 
microtubule-associated protein, and Fyn, a Src family kinase. In Alzheimer's disease, 
epileptogenesis is associated with an aberrant interaction between these two proteins. Fyn-Tau 
interaction involving PSD-95 will allow a rapid and excessive influx of Ca2+ via phosphorylation 
of N-methyl-D-aspartate receptor (NMDAR), which in turn, triggers downstream signaling 
leading to the hyperexcitability and neurotoxicity (Fig. 3) (8–11). These pathological changes 
will eventually perpetuate aberrant hyperexcitable neuronal circuitry resulting in seizures. 
Therefore, blocking this complex may be a potential therapeutic target for the treatment of 
epilepsy.  This can be achieved by characterizing the changes that occur after “status epilepticus” 
(SE).   
The goal of this thesis is to uncover the roles of Fyn and tau through analysis of the anti-
seizure effects that removal of these proteins has on three genetically engineered mice. The mice 
were treated with chemoconvulsant to generate status epilepticus (SE). The animals were 
grouped based on the genotype into four groups; wild type (WT), Fyn-/-, Tau-/-, and double 
mutant Fyn-/-+ Tau-/-. Their response to pentylenetetrazole-induced SE and its impact on gliosis 
and neurodegeneration were analyzed to understand the roles of Fyn and Tau. 
Thesis Organization 
This thesis is organized into three chapters. The first chapter contains an overview of 
epilepsy, and Fyn and tau pathology in epilepsy. The second chapter covers the results of overall 
experiments elucidate the effects of Fyn and/or Tau ablation towards an early phase of 
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epileptogenesis in PTZ-induced seizures mice model. Lastly, the final chapter wraps up the 
summary and future directions of this research.  
Literature Review 
Epidemiology of epilepsy and its classification  
Epilepsy the fourth most common neurological disorder worldwide ranked just below 
Parkinson's disease. Of the estimated, 50 million people worldwide are affected by epilepsy, with 
80% of affected patients residing in developing countries.  Higher prevalence and incidence rate 
of epilepsy in developing countries results from a higher incidence of predisposing conditions, 
such as infection (cerebral malaria, meningitis) and malnutrition that can lead to the permanent 
brain impairment. Also, the highest incidence has been shown to take place during early 
childhood and late adulthood (12).  In the USA, nearly two million people have epilepsy. 
Moreover, 3-5% of the general population potentially develop epilepsy at some point in their 
lives. Studies showed that up to 30% of epileptic patients do not respond to the current AEDs. In 
comparison, nearly 1.5 million people (prevalence of 0.5-0.6%) in Indonesia have epilepsy in 
which 440,000 cases are intractable epilepsy.  
Epilepsy syndromes are classified into two major groups, generalized and partial 
syndromes, that further subdivide based on the resulting type of seizure, EEG findings, and 
concomitant neurological features. The generalized type seizure is predominantly caused by 
maladaptive genetic elements that generate abnormal neuronal excitability emanating from both 
cerebral hemispheres. Although these mutations exert rather rare but intricate epilepsy forms, the 
major breakthroughs in the field of epilepsy were conceptualized through modeling these 
mutations on animal models. Mutated ion channels are shown to be the root cause of these 
syndromes that lead to hypersynchronized cortical neuron excitation. Most of the cases involving 
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these types of mutation termed “channelopathies," are intractable and yield the most severe 
forms of epilepsy in children such as autosomal dominant nocturnal frontal lobe epilepsy, Dravet 
syndrome, and benign familial neonatal convulsions (6,12,13).  On the other hand, partial 
epilepsies emerge from one or more localized foci that then further spread throughout the entire 
brain. The most common type of this syndrome in adults is mesial temporal lobe epilepsy 
(mTLE) as often manifested clinically in the form of a complex-partial seizure. The apparent 
hippocampal pathologies in mTLE are thought to coalesce as a consequence of one or more 
predisposing brain insults (3,6).         
Status epilepticus, epileptogenesis, and epilepsy 
"Seizure" is derived from Latin word "sacire” meaning “to seize upon” has been further 
defined as a paroxysmal activity that occurs due to hypersynchronization of groups of neurons in 
the brain (12,14). It manifests clinically with motor or non-motor activities, possibly occurring 
multiple times throughout a lifetime, and typically persists for second to minutes depending on 
the overall condition of the affected individuals (i.e., are ictogenic). In emergency cases, seizures 
can last for more than five minutes or are accompanied by a loss of consciousness so-called 
“status epilepticus” (15). Epilepsy is then described as the episodes of recurrent seizures that 
develop as a result of predisposing events. The process taken from the initial seizure event, 
caused by precipitating injury, to the first spontaneous recurrent seizure in the hyperexcitable 
area of the otherwise normal brain is defined as “epileptogenesis”. Research, spanning several 
decades, found that a seizure is an imbalance between the net excitatory and inhibitory impulses 
in the brain that can be provoked by either enhancing excitatory neurons or attenuating inhibitory 
neurons (16). Thus, AEDs are formulated to target corresponding ion channels in those specific 
neuronal populations, which in turn suppress seizure activity in the epileptic brain. Nevertheless, 
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the knowledge of epilepsy pathogenesis should be expanded beyond the simple the excitatory 
and inhibitory imbalance (17), concerning the ineffectiveness of available AEDs to prevent 
epileptogenesis (18).  
The basic mechanisms of seizure generation comprise two preceding events, which are 
characterized through the bursting action potential and resulting hypersynchronization. Bizarre 
neuronal activities are triggered by the influx of extracellular sodium (Na+) through a concurrent 
opening of voltage-gated Na+ channels following massive depolarization caused by an influx of 
calcium (Ca2+). These processes lead to the generation of repetitive action potentials that will be 
further transduced into spike discharges, observable through electroencephalograms (EEG) if 
sufficient synchronized activities from a group of neurons are detected. Under physiological 
conditions, the surrounding GABAergic interneurons counteract these bursting activities 
resulting in rather standard action potentials. The repetitive action potentials, however, could 
result in recruitment of other neighboring excitatory neurons. Thus, extracellular potassium (K+) 
is increased promoting further depolarization in excitatory neurons. Additionally, a consequence 
of the accumulated presynaptic Ca2+ is increased resulting in the release of excitatory 
neurotransmitters. Moreover, N-methyl-D-aspartate receptor (NMDAR) activation, mediated by 
sufficient depolarization, also contributes to the signaling cascade resulting in alteration of 
physiological functions of the affected neurons, further causing them to be more excitable. The 
loss of inhibitory neurons becomes evident as more neighboring excitatory neurons are being 
recruited. Multiple intrinsic and extrinsic factors can regulate neuronal excitability in the brain. 
Intrinsically, it could be affected by several mechanisms such as second-messenger signaling, 
cytoplasmic buffering, properties of ion channels, and protein expression. On the other hand, 
extrinsic factors such as the type and amount of extracellular neurotransmitters and their 
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receptors at synaptic terminals as well as the spatiotemporal properties of synaptic and 
nonsynaptic input, play important roles in maintaining the excited state of neuronal circuits 
(12,14). Furthermore, the aberrant reactivity of astrocytes, microglia (19), and loss of 
oligodendrocytes (20) can also drive glia-induced hyperexcitability and inflammatory events 
subserving recurrent seizures. Hence, the established re-entrant activation of a population of 
neurons may result in permanent changes to overall elements of neuronal circuits to be 
epileptogenic. This transformation from a previously healthy brain to the chronically 
hyperexcitable brain may require a latent period or otherwise occur subclinically after the brain 
insults (21). Moreover, therapeutic interventions could be addressed to intervene with the process 
of acquired epileptogenesis during this so-called latent period. 
Anatomy of the hippocampal formation  
Structurally, the hippocampal formation is a C- structure comprised of the hippocampus, 
dentate gyrus, subicular complex, and the entorhinal cortex (Fig 1A). The major excitatory inputs 
begin from the entorhinal cortex. The entorhinal cortex is bordered rostrally by the amygdala and 
caudally by anterior portion of the lateral geniculate nucleus. The entorhinal cortex refers to 
Brodmann area 28 neighboring with adjacent area 35, where the “transentorhinal” zone is formed 
(22). In the earliest preclinical stages of Alzheimer’s disease, this zone is frequently affected and 
attributed to the formation of neurofibrillary tangles (23). In humans, six-main layers of 
entorhinal cortex are distinguishable. Layer I is called the acellular layer or plexiform layer. The 
islands of stellate and pyramidal cells form layer II while more homogeneous pyramidal cells 
make up layer III. Layer IV contains bundles of distinctive cells called lamina dissecans. Below 
this lamina, a layer of cells is designated as layer V whereas layer VI is not clearly separated 
from layer V (24).  
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The C-like structure of the dentate gyrus is packed densely with the somas of excitatory 
granule cells (~15x106) constituting the granular cell layers (GCL) (25). Dendritic branches of 
these cells extend extensively alongside a small number of interneurons in the molecular layer of 
the DG that cover the regions superficial to GCL. In this layer, the perforant path afferent input 
from layer II entorhinal cortex synapse with the dendritic tree of granule cells (26). The 
innermost layer of the DG is called hilus containing a mixture of excitatory mossy fibers and 
inhibitory interneurons as well as a fraction of the pyramidal cell layer of the hippocampus 
enclosed by granule cells (27,28). The axons of mossy fibers project locally onto subjacent 
neurons in hilar regions and proximal dendrites of the hippocampus.     
Hippocampus means sea horse in Greek named by Giulio Cesare Aranzi while Cornu 
Ammonis is named after the horn of ancient Egyptian God "Ammon." The hippocampus itself is 
comprised of three main subfields so-called "Cornu Ammonis” 1, 2, 3 (CA1-3) (29). These 
hippocampal fields are compacted with excitatory pyramidal neurons constituting a layer called 
the pyramidal cell layer (PCL). The deep regions bordering the PCL is termed the stratum oriens 
containing various subtypes of interneurons and basal dendrites of pyramidal cells while their 
axons reside in the outermost subependymal fiber layer called the alvelus. Superficial to PCL, 
the regions are subdivided into stratum lucidum, stratum radiatum and stratum lacunosum-
moleculare that comprise the apical dendrites of pyramidal cells and interneurons. Stratum 
lucidum found only in CA3 comprises the mossy fibers originating from the DG synapse with 
proximal dendrites of pyramidal cells. On the other hand, stratum radiatum of CA3 and CA2 
pyramidal neurons receive associational histaminergic and cholinergic inputs from 
supramammillary and septal nuclei regions. Moreover, the stratum radiatum contains Schaffer 
collaterals that terminate along the perforant pathway from layer III of the entorhinal cortex on 
8 
 
 
stratum lacunosum-moleculare of CA1 (Fig. 1). Transitional region from CA1 comprised of 
pyramidal neurons with multiple complex projections to extra-hippocampal regions is called the 
subiculum. Its major projections are to the entorhinal cortex, nucleus accumbens, septal complex, 
anterior thalamus, and mammillary nuclei (24). 
Temporal lobe epilepsy (TLE), and epileptic circuits 
Once the central nervous system insults are instigated, acquired epileptogenesis begins to 
culminate. Several conditions are associated with the development of TLE such as tumors, 
traumatic brain injury (TBI) (30), infection,  stroke, Alzheimer’s disease (AD) (31) and genetic 
mutations may (32) potentially precipitate the aberrant neuro-glial homeostasis creating a pattern 
of temporal sclerosis that includes hippocampal atrophy. In some patients with TLE, olfactory 
and gustatory hallucinations accompanied by other symptoms such as loss of awareness and 
automatisms might precede the onset of seizures (33). Although not often, surgical temporal lobe 
removal could halt the seizures some patients but not all, implying that the involvement of 
aberrant microcircuits may be present.  
Alterations in the epileptogenic hippocampal network are marked by the loss of neurons 
in the DG and CA regions (34), gliosis, inflammation (19), and the ectopic adult neurogenesis 
(35) with far-reaching extra-temporal effects to neighboring areas such as the entorhinal cortex 
and amygdala (34,36). Cell death after the initial insults may cause synaptic reorganization in the 
hippocampus which is thought to be a part of epileptogenesis (2,37). These pathological features 
of TLE are evident in both human and animal models. In general, TLE is considered a suitable 
model of acquired epileptogenesis that can be modeled in the rodent following a wide variety of 
predisposing conditions as to mimic the pathogenesis occurring in humans.  
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Studies have been conducted to show the upregulation and downregulation of certain 
proteins and genes involved in the aberrant molecular mechanisms occurring after brain insults, 
during epileptogenesis, including immediate changes of ion channels expression in various 
neuroglial cells, corresponding neurotransmitters, and their receptors. At the circuit-level, axonal 
sprouting from the DG, misplacement of the DG and the generation of new pathological, 
recurrent excitatory synaptic connections (i.e., mossy fibers sprouting (MFS)) constitute the 
features of TLE. Aberrant MFS can form recurrent excitatory synapses between neighboring 
cells in the DG resulting in recurrent excitation (38,39) while several studies have shown that 
MFS is a beneficial property through the generation of new GABAergic interneurons (40–42). At 
the cellular level, astroglial and microglial activation together with neuronal cell death and loss 
of GABAergic inhibitory interneurons are the most common features of TLE. The loss of 
selective GABAergic interneurons, as well as loss of principal glutamatergic neurons (43), 
facilitate the incidence of spontaneous recurrent seizures after previously evoked seizures in TLE 
animal models (44). Some of these features might be involved in the pathogenesis of epilepsy 
leading to the development of hippocampal sclerosis whereas others could be the result of the 
overall pathological changes occurring in TLE. 
In epileptic circuitry, the process of neurogenesis is accelerated resulting in mal-
integration of newborn neurons. The ability of the brain to either strengthen or weaken the 
synaptic connections between the neurons provides an insight that modulating the brain plasticity 
could be an opportunity for the therapeutic intervention of epilepsy (45). Typical hippocampal 
excitatory loops begin at the neurons in the entorhinal cortex (EC) located in the medial temporal 
lobe that project to granule cell layers (GCL) of the DG via the perforant path. Following this, 
granule neurons in the DG synapse with pyramidal neurons in the CA3 via mossy fibers that go 
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to the CA1 and travel from CA1 to the subiculum and/or EC. CA3 also has recurrent collaterals. 
In addition to that, EC can directly excite CA3 via the perforant path and CA1 via the 
temporoammonic path (Fig. 2) (3,45). Robust interactions between inhibitory interneurons and 
excitatory neurons in the DG balance neuronal firing rates leading to maintenance of normal 
hippocampal firing (35,46). Thus, the inhibitory cell loss after SE (44,47), may perpetuate future 
seizure events resulting in the development of epilepsy. On the other hand, newly recurrent 
excitatory pathways have been formed after insults that the DG neurons excite themselves. The 
failure of the DG in stabilizing the de novo formation of recurrent excitatory pathways after brain 
insults may lead to epilepsy (39,48,49).  
As mentioned above, it is obvious that aberrantly integrated neurons in hippocampus play 
important roles in epileptogenesis. Additionally, several other conditions like TBI, stroke and 
other neurodegenerative diseases have been implicated in epileptogenesis with a variety of 
proposed molecular signaling pathologies (2,3,45). Moreover, in a clinical study performed on 
24 patients with TLE using fMRI, Haneef and colleagues found that there is also increased 
hippocampal connectivity to the limbic system, frontal lobes, angular gyrus, brainstem, and 
cerebellum. Consequently, this deep involvement of brain regions may explain how the burst of 
locally synchronous firing in temporal lobe can spread throughout the brain resulting in 
extensive damage to other parts of the brain (36).  
Models of seizure and epilepsy 
The aim of animal models of epilepsy is to recapitulate and mimic the electrographic 
signatures, histopathology, including neuroanatomical and biochemical changes, as well as 
genetic factors that occur in human epilepsy. No single animal model has been shown to 
represent the entire intricacy of epilepsy. Therefore, a wide variety of animal models has been 
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developed to achieve construct validity (underlying disease), face validity (phenotypic 
properties), and predictive validity (clinical treatment response) in human epilepsy counterparts 
(50). The most common animal model used to study epilepsy are the rodent models, such as the 
rat (Rattus norvegicus) and mouse (Mus musculus), owing to their rapid breeding capacity, small 
size, and docility. Additionally, the lower vertebrate such as Danio rerio (Zebrafish) (50) and 
invertebrate Drosophila melanogaster (51) are utilized more commonly to model acute seizures 
and genetic epilepsies. In genetic models, seizures can develop spontaneously (52–54), or be 
provoked by cues (55). In other animal models, seizures are induced by administration of 
chemoconvulsants or electrical stimulants.  
Acute or chronic seizures models can be elicited in animals. While chronic seizure 
models are best suited for modeling TLE in human as a part of neurodegenerative processes, 
acute seizures are studied extensively to explore the underlying mechanisms of seizure 
generation after insults. Several agents like penicillin, pentylenetetrazol (PTZ), tetanus toxin, 
strychnine, N-methyl-D, L-aspartate are used to model acute seizures which are instrumental for 
the discovery of currently used AEDs that target ion channels and receptors (56,57). Particularly, 
PTZ used to model acute clonic seizures in rodents is a gamma-aminobutyric acid receptors type 
A (GABAA) receptor antagonist. A single dose of PTZ results in the generation of acute, rather 
than chronic, spontaneous seizures (58), thereby allowing researchers to study the early 
epileptogenic events (59).     
Aside from the drugs used for acute seizure induction, maximal electroshock (MES) is 
used to model generalized tonic-clonic seizures (56). In chronic seizure models, kainic acid and 
pilocarpine are the two most common compounds used for TLE induction in rodents (50,60). 
Acute seizures can eventually evolve to be recurrent chronic seizures, so-called epilepsy, via the 
12 
 
 
kindling process. Kindling refers to application of electrically or chemically repetitive sub –
convulsive stimulus that leads to the progressive development of increased seizure susceptibility 
(60,61). This process is best suited to study the sequence of epileptogenesis as well as the 
neuropathological phenomenon in poorly controlled epilepsy (62). 
Gliosis and epilepsy 
The Human brain consists of nearly 75% of glial cells, oligodendrocytes being the most 
abundant glial cell, followed by astrocytes and microglia (63). It becomes evident that 
inflammatory mediated glial cells can promote hyperexcitability and hypersynchrony in epilepsy 
in human and experimental animals (64). While the highly selective blood-brain barrier (BBB) 
protects the CNS from any catastrophic events, this immune-privileged CNS can be 
compromised leading to epileptogenesis as result of the dysregulation of glial function that 
makes up the BBB (65). Glia exert a wide variety of roles including acting as scaffolds for 
neuronal migration, modulators for synaptic pruning and plasticity, regulators of 
neurotransmitters, ions, water concentrations, and contributing to axonal insulation, a part of the 
BBB integrity functions(66,67), and brain immunity (68). Thus, glia is urgently essential in 
regulating physiological brain homeostasis.  
Aberrant glial functions like glial scars, activated microglia, and astrocytes resulting in 
disruption of BBB integrity and increased production of inflammatory agents are prominent in 
the epileptic brain (69). Chronically uncontrolled glial-mediated inflammation can lead to the 
establishment of epilepsy through strengthening the hyperexcitability of the epileptic circuit by 
direct alteration of synaptic transmission. Gliosis can also induce neurodegeneration (70) and 
eventually perpetuate ictogenic events, which in turn can result in a prolonged inflammatory 
state in the brain. The overall means by which gliosis modulates the phenomenon and 
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epiphenomenon of neuronal pathology in epilepsy depends on the severity, location of brain 
insults, time frame, and particular molecular signaling. 
Reactive astrogliosis contributes to epileptogenesis through changes in morphology, 
molecular contents and proliferation state. Morphologically, astrocytes become enlarged and 
have more processes emerging from their soma as they become reactive (71). Also, their 
functional properties such as enzyme content, transporter systems, and the capacity of K+ 
buffering are compromised during epileptogenesis (72). Accumulating evidence suggests that the 
extracellular space (ECS) K+ level and ECS volume are associated with neuronal excitability 
(73–75). Aquaporin-4 (AQP4), a water channel in astrocytes that regulate ECS volume and the 
interstitial fluid osmolarity, is implicated in the pathogenesis of epilepsy as its dysfunctions lead 
to increased susceptibility to seizures (74,76). On the other hand, reduced K+ spatial buffering 
due to impairment of inward rectifying K+ channels 4.1 (Kir 4.1) may help cause glial pathology 
in both acquired and genetic epilepsy (72). Conditional knockout of Kir 4.1 is sufficient to 
generate seizure-like behavior through inhibition of potassium and glutamate uptake with the 
potentiation of synapses (52). Moreover, downregulation of astrocytic glutamate transporters 
(GLT) impairs the glutamate uptake mechanism by astrocytes, which is imperative to the 
regulation of synaptic crosstalk, thereby increasing epileptic hyperexcitability. A defect of the 
certain enzymes that contributes to glutamate homeostasis is also tightly coupled with the 
incidence of seizures like glutamine synthetase (GS) as a gene mutation resulting in the 
deficiency of GS exacerbates severe seizure activity in children.  
The BBB and vasculature dysfunctions are also part of epileptogenesis since astrocytes 
constitute BBB by wrapping around endothelial cells. The alteration of BBB permeability is 
highly correlated with seizure events. These changes can be precipitated by pro-inflammatory 
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chemokines and cytokines released from reactive astrocytes like vascular endothelial growth 
factor (VEGF), interleukin-1 beta (IL-1β), thus enhancing microvasculature impairment. As a 
result, plasma albumin leaks to the interstitial tissue causing downregulation of GLT-1 and Kir 
4.1 in astrocytes and eventually subserves the inflammatory milieu (77). The production of IL-1β 
and high-mobility group box 1 (HMGB1) will activate IL-1 receptor/ Toll-like receptor 
(IL1R/TLR) system enhancing seizure onset and frequency, whereas blocking it shows beneficial 
effect toward seizures severity. Furthermore, these signaling events will activate NMDR through 
phosphorylation of NR2B subunit by Src-kinase leading to hyperexcitability and neuro-
excitotoxicity (78,79).  Overall, astrocytes contribute to innate immune response in the brain 
along with microglia in which they seem to activate one another during inflammation (80).  
Microglia, on the other hand, is a specialized macrophage, which mediates the humoral 
and cellular immune system and phagocytosis in CNS (81). As the frontline innate immune 
response, activated microglia serve as a constant scanner for brain and spinal cord micro-
damages (68). During development, microglia plays important roles including synaptic pruning 
(82), clearance of death cells, and neurogenesis as well as oligodendrogenesis (83), thereby 
highlighting the micrioglial importance to early neural circuit development. In adult brains, 
microglia also contribute to the learning and memory process, cognitive function and synaptic 
plasticity (84). In epilepsy, however, the microglia become activated that then exert some 
deleterious effects while others show anti-inflammatory properties depending on precise timing 
and the severity. Alteration of microglia morphology is prominent during epileptogenesis 
characterized by enlarged soma and retracted processes in contrast with surveillant microglia 
which show highly ramified processes and stellate shape (small soma) (85). These morphological 
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changes and upregulation of IBA1, CD68, or CD11b, markers for microglia, are observed within 
24 h after chemo convulsant exposure (86). 
The activation of microglia reduce seizure threshold by producing proinflammatory 
substances, therefore accelerating the generation of recurrent seizure episodes. Microglial 
activation is well studied by administration of lipopolysaccharide (LPS), a TLR ligand. 
Activation of TLR4 by LPS can induce the release of (IL-1β) which in turn produce the 
epileptiform discharge in vivo and ex vivo in rodent animal models (87,88). Furthermore, 
enhanced microglial function is integral to the inflammatory state during acute epileptogenesis. 
Nonetheless, whether it is beneficial or detrimental remains highly debatable (89). Delayed 
neurodegeneration in epilepsy seems to be partially mediated by activated microglia since the 
inhibition of microglial fractalkine receptor signaling reduces neurodegeneration in epilepsy 
model (90). Also, activated microglia increase the aberrant neurogenesis which is one of the 
hallmarks of epilepsy while minocycline administration suppresses the activation of microglia 
resulting in significant reduction of neurogenesis in pilocarpine-induced seizure model (91). 
Overall, mounting evidence of glial-mediated excitation and inflammation leading to 
epileptogenesis is thought to be the overlapping and reciprocal mechanisms as inflammation can 
induce excitation and vice versa.  
Fyn, tau, and epilepsy 
In the human CNS, Fyn is mostly found in neurons with moderate expression in glial 
cells (92–94). Recently, it is known to reside in microglia and upregulated during inflammatory 
state (95). As a non-receptor Src-family tyrosine kinase, Fyn plays crucial roles involving the 
development of CNS and its functions (96–100), and also non-neuronal systems like immune 
systems (101,102). In human, Fyn is encoded on chromosome 6q21, with three splice variants, 
16 
 
 
which FynB isoform is highly expressed in the brain (103). Fyn fundamentally relies on the 
complexity of tyrosine phosphorylation-dephosphorylation mechanisms and the variations of its 
N-terminus and Src Homology 4 (SH-4) domain to carry out its function (104). Multiple proteins 
including Tau and its SH (SH 1-4) domains are involved in modulating overall functions of Fyn. 
Physiologically, Fyn regulates T-cells signaling (102), cell division, cell adhesion process, 
proliferation, cell survival and differentiation (105). Notably, in the CNS, Fyn contributes to the 
process of neuron myelination by oligodendrocyte (92,94), astrocyte migration (106), synaptic 
maturation, and plasticity. Therefore, Fyn is essential for neurodevelopmental properties 
including learning and memory acquisitions. Of specific interest for epilepsy are the 
involvements of Fyn concerning its roles in synaptic functions. Since excessive excitation mainly 
causes epilepsy in the brain, the interactions between post-synaptic density proteins (PSD) are 
thought to be associated with this pathology. Researchers have linked the localization of Fyn in 
the post-synaptic site to the excitation-facilitated N-methyl-D-aspartate-type glutamate receptor 
(NMDARs) involving PSD-95. Fyn mediates synaptic plasticity and glutamate trafficking by 
phosphorylating the specific subunits of NMDRs named NR2A and NR2B (96–100,107). In 
addition to that, it is also reported that Fyn phosphorylates γ-aminobutyric acid (GABA) 
receptors (GABA) on specific subtypes (108). Knocking out Fyn in mice models results in 
memory deficits and impairment of long-term potentiation (LTP) (98,100). Furthermore, 
morphological retraction of dendritic spines occurs in Fyn knockout mice (109). Some other 
evidence of deleterious effects of lacking Fyn has been reported including post-natal 
corticogenesis defects like hydrocephalus (110) and retinal defects (111). All these corroborate 
the crucial physiological functions of Fyn in facilitating synaptic integrations during the 
development of CNS.  
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As discussed above, enhancing the activity of Fyn can potentiate excitatory activity in the 
neurons through NMDARs rendering Fyn capabilities to promote further hyperexcitation and 
neurotoxicity in epileptic brains. Experimentally, it has been shown that the expression of 
hippocampal fyn mRNA is increased during status epilepticus (93). Reduction of Fyn activity 
may, therefore, have neuroprotective effects against seizures while a profound reduction can lead 
to the neurodevelopmental defects. Moreover, a Src-kinases inhibitor has undergone clinical trial 
as a neuroprotective agent to cure Alzheimer’s Disease (AD) (112). Conflicting results, however, 
regarding effects of Fyn reduction in epilepsy have been reported. One shows that mice lacking 
Fyn have a higher susceptibility to chemo-convulsant induced seizures as compared to wild-type 
mice (97) whereas another group stated that Fyn deficiency has anti-epileptic property (113). 
Despite the contradiction, it is imperative to thoroughly examine the integrative roles of Fyn in 
CNS with detail manner. Generating potential therapeutic approaches concerning Fyn against 
epilepsy is thereby achievable. 
Tau, a microtubule-associated protein, is functionally implicated in microtubule 
assembly. First discovered 1975, this natively unfolded protein is vital for stabilizing dynamics 
of microtubules and promoting axonal growth (114). Topographically, it assembles throughout 
the axon in mature neuron while it is firstly concentrated in the cell body and neurites of 
immature neurons, but later some evidence points out the expression of tau in somatodendritic 
sites, a nucleolar organizing region of neuronal cells (115). Furthermore, it is also found in 
moderate abundance in astrocytes (115), microglia and oligodendrocytes (116) as well as 
extracellular compartments (117). In human, Tau is located on chromosome 17q21 and has six 
isoforms generated (2N4R, 1N4R, 0N4R, 2N3R, 1N3R, 0N3R) from alternative splicing of exon 
2, 3 and 10 (118) which are further grouped based on carboxyl-terminal repeat domain (3R or 
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4R). In contrast, mice brain only express 2N4R, 1N4R, 0N4R isoforms and one isoform of 3R in 
newborn. Tau regulates reorganization of the cytoskeleton by binding to α-tubulin–β-tubulin 
heterodimers as well as dynamic of axonal transport through dynein and kinesin mobilization.  
Moreover, it has been experimentally validated that Tau affects axonal growth and elongation as 
mice with Tau deficiency exerts slowed maturations of neurons and retracted neurites spines 
(119). Although it seems essential for CNS maturation, one study showed questionable results as 
a particular Tau knock-out mice line used in the study do not exhibit any of those indicated 
defects (120).  
Structurally, Tau possesses identified proline-rich regions with PXXP motifs where the 
SH3 domain of Fyn binds (121). Like Fyn, Tau functions are dynamically regulated by the 
process of phosphorylation and dephosphorylation at multiple phospho-epitope sites during 
development (122) resulting in microtubule stabilization. Tau can be phosphorylated on 85 
locations (80 Ser or Thr, and 5 Tyr) with approximately 17 motifs attributed to AD and other 
tauopathies (123). Moreover, several kinases have been identified that contribute to 
phosphorylation of Tau such as cyclin-dependent kinase 5 (cdk5), glycogen synthase kinase-3 
(GSK-3), and casein kinase 1 (CK1) (123,124). Unfortunately, a wide variety of diseases so 
called tauopathies including AD and epilepsy can occur as a result of Tau hyperphosphorylation 
leading to destabilization of microtubule and aggregation of tau (9,54,55,125,126). In chemo-
convulsant induced-epilepsy mice models, increased hyperphosphorylation of tau was observed 
at multiple different residues such as Ser 199/202, Thr 205, Ser396, Ser422, Thr212, Thr217, 
Ser262 (125,126). Contrarily, mice with epilepsy due to genetic defects in ion channels, neither 
showed any changes in total Tau nor the phosphorylated Tau levels when compared to the 
wildtype control mice (54,55). Moreover, several of similar phospho-epitopes are also identified 
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in resection of human temporal lobectomy tissue with epilepsy (127). Convincingly, it is evident 
that hyperphosphorylation of tau perpetuates disease progress in epilepsy. This pathological 
phenomenon may be translated into diseases’ symptoms through complex mechanisms between 
Tau and its interaction protein partners. Lee et al. reported that phospho-Tau interact with the 
SH3 domain of Fyn in neurons. Fyn also phosphorylates Tau on Tyr 18 and the bound form of 
this interaction is strengthened in the presence pathological conditions like AD and 
Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP 17) (121,128). The 
similar mechanistic ways have been proposed from two independent groups delineating 
involvement of tau-Fyn interaction and PSD-95 as they mediate hyperexcitability and 
neurotoxicity through phosphorylation of NMDR in the PTZ-induced seizures of AD mice model 
(9,10,129). Apparently, phospho-Tau serves as a chaperone to localize Fyn to postsynaptic sites. 
Attaching to phosphor-Tau, Fyn then phosphorylates NR2B subunit of NMDRs at Tyr 1472 
enabling the stable formation of Fyn-tau-PSD-95 and NMDR complex (Fig. 3). As the result of 
this complex, a massive influx of cations (Ca2+, Na+) to the affected neurons will lead to the 
various downstream cell signaling including neurodegeneration and hyperexcitation, thereby 
potentially generating epileptic symptoms in AD patients (9). Although tau knockout mice may 
have potentially deleterious effects on neurodevelopment and neurogenesis (119,120,130,131), 
accumulated evidence validates neuroprotective features of tau reduction regarding seizures 
(9,10,54,55,125,129,132). Furthermore, no behavioral deficit is detected in aged Tau knockout 
mice showing a long-term neuroprotective mechanism of Tau reduction (133). Overall, epilepsy 
is amenable to therapeutic innervations that could be addressed by targeting Fyn and Tau 
interaction as well as inhibiting PSD-95 and NMDRs that could also theoretically exert the same 
neuroprotective effects.  
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Figures and Legends 
Figure 1. Coronal section of hippocampus in human (A, figure from Schultz and 
Engelhardt, 2014) and rodent (B, figure from Allen Brain Atlas). Abbreviations- Alv = 
Alveus; CA1–CA3 = sectors of the Ammons horn; DG = dentate gyrus; EC = entorhinal cortex; 
FF = fimbria/fornix; h = hilus of the dentate gyrus; mf = mossy fibers; pp = perforant pathway; 
sub = subiculum; PRC = perirhinal cortex; sc = Schaffer collaterals (24). 
 
 
 
 
 
  
 
  
       
 
Figure 2. Loop structure of the hippocampus. Two major inputs to hippocampus are derived 
from the perforant path (PP) and the temporoammonic (TA) pathway. The outputs are received 
by entorhinal cortex (EC) generating multiple excitatory loops. EC supplies inputs to the dentate 
gyrus (DG) via the PP. Then, they travel from the DG to CA3 subfield via mossy fibers (MFs), 
from CA3 to CA1 and from pyramidal cells layer of CA1 to the subiculum (not shown) and/or 
EC. Bundles of circuits originating from EC projects to CA1 subfield (via the TA pathway) and 
travels back to the subiculum and/or EC creating a short loop. An additional intermediate-length 
loop created by projections from the EC to CA3 (via the PP pathway) to CA1 and back to the 
subiculum and/or EC is shown. Pyramidal cells in CA3 also display recurrent collateral 
projection between themselves (3).  
32 
 
 
 
 
 
 
       
 
 
 
 
 
 
 
 
Figure 3. Conceived Pathomechanisms  (adapted from Ittner et al. 2010). Fyn is localized by 
phosphorylated Tau to the postsynaptic membrane following seizure where it phosphorylates (P) 
NR2b of NMDAR at Y1472. This phosphorylation mediates the involvement of scaffolding 
protein PSD-95. This interaction stabilizes the opening NMDAR resulting in neurodegeneration 
and hyperexcitability due to an excessive influx of Ca2+ and Na+ (9). 
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Abstract 
Epilepsy is one of the four most common neurological disorders, which is characterized 
by unprovoked recurrent seizures. Fyn-tau interaction has been associated with 
neurodegenerative changes in Alzheimer's disease (AD). While the genetically ablated Tau 
appears to be protective against seizures in AD models, the roles of Fyn and tau in the early 
phase of epileptogenesis in seizure models are not clear. Particularly, it is still unknown whether 
a combination of Fyn and tau reduction can exert a more profound neuroprotective effect. Here, 
we demonstrate the effects of genetic deletion of Fyn and/or tau in the early phase of 
epileptogenesis using pentylenetetrazole (PTZ)-induced epilepsy mouse model. We examined 
three genetically engineered genotypes; Fyn-/-, Tau-/-, double mutant Fyn-/-+Tau-/- within the first 
24h after seizure induction. All knockout mice reduced the severity of seizures and prolonged the 
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latency to the onset convulsive seizures (CS), stage 3 and above with the most prominent effects 
observed in Tau-/- mice and double mutant Fyn-/-+ Tau-/- mice in contrast the wildtype (WT) 
control mice. The Fyn-/- mice, however, showed higher mortality, in < 20 min of seizure 
induction, in contrast to the other knockouts (KO) and the WT. Despite this unexpected finding, 
all KO groups immunohistochemically exhibited a reduction in hippocampal neurodegeneration 
and reactive gliosis. Also, in all KO mice, the parvalbumin-GABAergic interneurons in the 
hippocampus and entorhinal cortex were resistant to PTZ injection, while their numbers 
significantly reduced in the WT. In the hippocampus, the level of inwardly rectifying potassium 
(Kir 4.1) channels was significantly downregulated in the astrocytes in the WT mice treated with 
PTZ, while its level was unaffected in all KO groups. Overall, our results indicate that disabling 
the Fyn and/or tau displays neuroprotective effects against pathological changes in the 
hippocampus at the early phase of epileptogenesis. 
Introduction 
Epilepsy is the recurrence of unprovoked seizures that affects approximately 50 million 
people worldwide (1). It could be initiated by brain insults that may result in status epilepticus 
(SE) which is a medical emergency associated with high morbidity (epilepsy), if not mortality 
(2). Although most of the treatments for epilepsy were designed to target ion channels to 
suppress seizures activity, a drug-resistant seizure was reported in 25 - 50% of epileptic patients 
(3,4).  
A high incidence of epilepsy in Alzheimer's disease (AD) is linked to Fyn and tau. 
Studies showed that tau protein, a member of the microtubule-associated protein family, has 
been associated with the regulation of neuronal hyperexcitability (5–10) while Fyn, a member of 
the Src family of kinases, is thought to interact with tau through its N-terminal domain (11–13). 
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While tau is typically involved in cytoskeletal and intracellular trafficking functions including 
microtubule stability, transport, and signal transduction (14,15), Fyn kinase has been involved in 
widely diverse downstream signaling pathway in the formation of the central nervous system, 
amygdala kindling (16) and peripheral immune system (17). Past studies showed that tau 
removal attenuates the severity of seizures in drug-induced seizures as well as the genetic model 
of epilepsy (5–7,9,18–20). Additionally, targeting tau with the pharmacological agents also 
limits the excessive network firing after seizures induction (21). On the other hand, Fyn 
deficiency reduces mortality (22,23) and suppresses the microglia-mediated neuroinflammation 
in AD model (24) as well as in Parkinson's disease (PD) model (25). Moreover, the expression of 
astrocytic Fyn increases during the inflammatory state in kainic acid (KA) induced seizures 
model (26), and also in AD model (27). These studies showed the involvement of Fyn in the 
pathogenesis of aberrant cellular and circuitry changes during seizures. In epilepsy, Fyn is 
required to generate seizures in epilepsy kindling models (16,28). Conflicting reports regarding 
Fyn contribution in epilepsy, however, exists as other studies showed that Fyn reduction has no 
effect on seizure activity (28) or even increases seizure susceptibility induced by an acoustic 
stimulant (29) and various chemoconvulsants (30).  
In AD, axonal tau undergoes hyperphosphorylation, detaches from microtubule and 
migrates to the soma and dendritic compartment. Afterward, dendritic pathological tau serves as 
a protein scaffold to deliver Fyn to the postsynaptic sites (12,31) while also serving as a Fyn 
phosphorylation substrate (Tyr 18) (12). This complex then allows Fyn to phosphorylate N-
methyl-D-aspartate receptor (NMDA) receptors through NR2B subunit at Y1472 resulting in the 
stabilization of the interaction between NMDA receptor and postsynaptic density proteins 95 
(PSD-95). This interaction allows the influx of Na+ and Ca2+ that lead to hyper-excitatory 
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synaptic potentials and neurodegeneration (7,31,32). Neurodegeneration and hyperexcitability 
resulting from these pathogenic events may also involve activation of glia and loss of 
GABAergic interneurons, which are the most common pathogenic features of human TLE 
(33,34). As reactive astrocytes evolve, the downregulation of glutamate transporter (GLT) and 
inwardly rectifying potassium channel 4.1 (Kir4.1) take place (35,36). As a consequence, 
reduction of Kir 4.1 causes impairment of K+ clearance and glutamate uptake leading to 
epileptiform discharge and epilepsy phenotype (37–39). On the other hand, activated microglia 
release pro-inflammatory cytokines such IL-1β, iNOS, and can perpetuate hyperexcitability and 
epileptic state (40–43).  
There is a paucity of information, however, about whether the co-pathogenic interaction 
of Fyn and tau has direct influences on those hallmarks of epileptogenesis above on the cellular 
level and whether disruption of this complex can exert beneficial effects. Therefore, it is 
imperative to elucidate the individual as well as combined roles of Fyn and tau during 
epileptogenesis. We analyzed the effects of Fyn and tau using genetically modified mice; Fyn-/-, 
Tau-/-, double mutant Fyn-/-+ Tau-/- on video-recorded seizures activity post- GABAA receptor 
antagonist pentylenetetrazole (PTZ) administration. At 24 h after the seizure, 
immunohistochemistry and western blot were performed to observe and compare the cellular 
changes that occur in each group. Reducing these proteins suppresses the seizure severity along 
with and corresponding pathological changes such as gliosis, neurodegeneration, and loss of 
GABAergic interneurons in the acute phase of epileptogenesis. Our results highlight the 
involvement of Fyn and tau in the early phase of epileptogenesis that supports our hypothesis of 
pro-epileptogenic roles of Fyn and tau. 
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Materials and Methods 
Animal source  
Homozygous Fyn-/- mice bred on hybrid S129 x C57BL/6J strains background purchased 
from Jackson Laboratory as well as Tau-/- C57BL/6J background (44) were both obtained from 
Dr. Gloria Lee (Department of Internal Medicine, University of Iowa). Heterozygous Fyn-/+ and 
Tau-/+ were crossed to generate mice with no (Fyn-/-, Tau-/-), one (Fyn-/+, Tau-/+), and two 
(Fyn+/+, Tau+/+) normal Fyn and tau alleles. We used double knockout (Fyn-/-, Tau-/- ), Fyn-/-,  
and Tau-/-  mice in our experiments. The Fyn+/+ and Tau+/+ mice served as wild-type control mice 
in this study. Western blot confirmation was performed to verify the corresponding protein 
expression in WT and mutant background (Fig 1B).  Twelve weeks old mice of either sex were 
used in the experiments. All mice were housed on a regular cycle of 12 hours light/ 12 hours 
dark at 220 C with free food and water access in Laboratory of Animal Resources at University 
of Iowa. Institutional Animal Care and Use Committees of University of Iowa (IACUC), Iowa 
City, approved all procedures. Immunohistochemistry and Western Blot experiments were 
carried out at Iowa State University. 
Pentylenetetrazole-induced seizures and behavioral scoring 
GABAA receptor antagonist pentylenetetrazole (PTZ) (Sigma) prepared sterile in 
phosphate-buffered saline (PBS) at a concentration of 4 mg/ml was injected intraperitoneally. 
The dose of 40 mg/kg was used to induce status epilepticus (SE). After PTZ injection, all mice 
were placed in the cage for 20 minutes behavioral seizure observation with video recording (19). 
The examiners were blinded to the genotypes of the mice when analyzing the videotape /direct 
observation and quantifying the seizure severity based on published scoring criteria of seizures 
(45,46). The modified version of Racine scaled was used: 0, normal activity; 1, rigid posture or 
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immobility; 2, stiffened or tail extension; 3, rearing with facial and manual automatism a well as 
partial body clonus, including forelimb clonus; 4, rearing and falling; 5, tonic–clonic seizures 
with loss of posture or bouncing (Fig 2A). Stage 1 and 2 were further classified as non-
convulsive seizures whereas stage 3 to 5 classified as convulsive seizures (45,47).  
Tissue processing and immunohistochemistry  
The mice assigned for immunohistochemistry (IHC) were euthanized at 24 h post-PTZ by 
an overdose of pentobarbitone (60 mg ⁄ kg, i.p.) (Fig 1A). Trans-cardiac perfusion with 4% 
paraformaldehyde (PFA) in PBS was carried out on the mice to fix the tissues. The brain was 
then harvested, post-fixed for 4h in 4% PFA. Afterward, the fixed brain was cryopreserved in 
20% sucrose and stored at 40 C overnight. Brain tissue was then embedded in gelatin embedding-
solution (PBS containing 0.1% sodium azide, 7.5% sucrose,  15% porcine gelatin), stored 
overnight at 40 C, and wrapped with Saran wrap to prevent desiccation. After that, the tissue 
blocks were mounted on 20-mm cork discs (Electron Microscopy Science) with optimal cutting 
temperature for frozen tissue specimen, quickly immersed in liquid nitrogen liquid nitrogen-
cooled isopentane until fully frozen, store at -20 before cryosectioning. Frozen tissue blocks 
were sectioned coronally (15 µm) on a cryostat (Cryostar NX70, ThermoScientific, MA, USA) at 
blade temperature of -200 C and a block temperature of -200 C. Obtained brain slices were 
mounted sequentially onto pre-coated glass slides with chrom-alum-gelatin (four sections/slide, 
225 µm apart for mouse brain) as described previously (48,49). Thus, it allows sequential tissue 
collections that represent rostral-caudal aspects of the brain in a single slide. The slides were then 
stored at 40 C fridge until IHC analysis performed.  
 Brain sections were subjected to antigen retrieval by immersion in pre-heated citrate 
buffer to 900 C containing 10 mM citric acid, 0.05% Tween 20, and pH 6 for 20 minutes prior to 
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IHC. Sections were then washed few times to remove PFA traces, blocked with PBS containing 
10% donkey serum and 0.02% triton-X100 for 1 h at room temperature to avoid non-specific 
binding. Double or triple immunolabeling was performed on control groups, and PTZ treated 
groups using the same reagents and antibodies. Afterward, primary antibodies mixed in PBS 
containing 2.5% donkey serum, 0.25% sodium azide, 0.1%, Triton X-100sections were added to 
the sections for 16 hours incubation at 40 C. The primary antibodies; anti-parvalbumin (1:1000, 
rabbit, Abcam, USA), anti-IBA1 (ionized calcium binding adaptor molecule-1, 1:400, goat, 
Abcam, USA), anti-GFAP (glial fibrillary acidic protein, 1:400, mouse, Sigma, USA), anti-Kir 
4.1 (1:250, goat, Santa Cruz, USA), anti-NeuN (1:400, rabbit, EMD Millipore, USA), anti-Fyn 
(1:500, rabbit, Santa Cruz, USA), anti–phospho-PHF-tau pSer202+pThr205 clone AT8 (1:500, 
mouse, Pierce, USA) were used. Following day, sections were PBS-washed sufficiently and 
incubated with either CY3/FITC conjugated or biotinylated secondary antibody at room 
temperature for 2 h. Secondary antibodies (Jackson Laboratories, USA) were applied; either with 
fluorescent-conjugated dyes (FITC, 1:80 or CY3 1:300) or biotinylated secondary antibody 
(1:400). After washing six times with PBS following incubation with biotinylated secondary 
antibodies, sections were treated with streptavidin diluted in PBS (1:300 for CY3 and 1:100 for 
FITC, Vector Laboratories, USA) for 45 min and then thoroughly rinsed with PBS. Sections 
were then nuclear-stained with 4′,6-diamidino-2- phenylindole (DAPI®, Vector Laboratories, 
USA) and cover-slipped. A negative control was the sections without primary antibody staining 
while a positive control was other brain regions stained with both primary and secondary 
antibodies (e.g. thalamus for IBA1). 
Degenerating neurons in the hippocampus, the entorhinal cortex brain sections were 
identified using NeuN and Flour Jade B (FJB) double staining. The sections were processed for 
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NeuN immunolabeling as described above. Afterward, FJB staining was performed following the 
modified protocol from previously published studies (48,50,51). Rehydration of sections was 
then carried out following this order; 3 min immersion in 100% ethanol, 70% ethanol, 1 min 
immersion in distilled water. Sections were oxidized in 0.006% solution of potassium 
permanganate (KMnO4) for 10 minutes on a shaker. After couples of rinse in distilled water for 1 
min, sections were transferred to 0.1% acetic acid containing a 0.0003% solution of FJB for 10 
min with gentle shaking in dark settings. Sections were rinsed with distilled water three times, air 
dried for 3 h, cleared wit xylene, and mounted with a hard mounting medium, acrytol (Surgipath, 
Leica Biosystems, IL).     
Microscopy and cell quantification for immunohistochemistry 
Immunostained sections were visualized using an inverted fluorescence microscope 
(Zeiss Axiovert 200), and images were captured with Hamamatsu digital camera (Model C-
10600-10B) and processed with HCImage live (version 4.1.2.) software. The photographs were 
taken at multiple magnifications (10x, 20x, 40x) with consistent exposure time. Image J was 
used to determine counting area (mm2) and blind cell counts (52). A bilateral quantitation of 
immunopositive cells with a visible nucleus (DAPI+) was undertaken from a minimum of eight 
sections per animals as previously described involving rostral to caudal aspects of the 
hippocampus and entorhinal cortex (48,49,53). The Abercrombie correction was applied to the 
quantification to overcome the over-counting bias resulting from consideration of cell fractions 
as whole cells (54). The mean width of 20 randomly DAPI- positive nuclei was calculated in 
each section. The corrected cell counts were then obtained from the following equation: adjusted 
counts = raw counts x [thickness of the section ⁄ (width average of 20 nuclei per section (µm) + 
thickness of the section (µm))].  
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Image acquisition and skeleton analysis of microglia 
A microglial morphometric analysis using skeletonization method was carried out to 
quantify microglia morphology in IHC images of the hippocampus. A modified method was 
adopted from published studies (55,56). The images of IBA1+ sections were captured on 40x 
lens using Zeiss Axiovert 200 inverted fluorescent microscope. A series of images with multiple 
focuses photographed on the same field were stacked manually (10 images in total) using “Stack 
Focuser” plugin (http://imagejdocu.tudor.lu/) to create a single image with enhanced 
visualization of microglia processes. Images were randomly sampled from anterior, middle and 
posterior regions of the hippocampus. Afterward, resulting images were loaded onto ImageJ 
software, despeckled to eliminate background noise. Fluorescence intensity in each image was 
kept consistent to minimize variability of measurement. The cell body area of each microglia in a 
given image was determined after converting the pixel scale into micrometer (µm). The image 
was then binarized and skeletonized using ImageJ software. The Analyze Skeleton plugin 
(http://imagejdocu.tudor.lu/) was used to obtain data on the number of endpoints and the longest 
processes path per cell on the frame. Approximately, 50-70 microglial cells were analyzed in 
each group.        
Fluorescent western blotting 
 The fresh hippocampal tissue lysates were prepared on wet ice (4 °C) by homogenizing 
the tissue using Tissue Ruptor (Qiagen, USA) in a cocktail of RIPA buffer and protease and 
phosphatase inhibitors (Thermo-Scientific, USA). Normalization of the lysates was performed by 
employing the Bradford protein assay to validate equal protein amount. Each sample with the 
equivalent amount of hippocampal tissue proteins was processed by loading and separating the 
proteins on 4% stacking gels with either 10% or 15% resolving, using SDS-PAGE (sodium 
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dodecyl sulfate-polyacrylamide gel electrophoresis) method. Compartmentalized proteins on the 
gels were transferred to a nitrocellulose membrane overnight at 4 °C. Membranes were then 
washed several times in wash buffers (0.05% Tween in PBS (PBST)) and performed 1h- 
blocking at 25 C with a specific blocking buffer for fluorescent Western blotting (Rockland 
Immunochemicals, USA). Incubation of membrane with primary antibodies was carried out for 
16 h at 4 °C. The Primary antibodies such as anti-Kir 4.1 (rabbit, 1:1000), anti-tau clone Tau5 
(mouse, 1:3000), anti-Fyn (mouse, 1:1000) and β-actin (1:10,000, Sigma, USA) for loading 
control were used. After several washes, an infrared dye-tagged secondary antibody either 680 
nm or 800 nm (1:10,000, LiCor, USA) was applied for 1 h. Odyssey IR imaging system (LiCor, 
USA) was used to view the binding of antibodies. ImageJ software was used to analyze quantity 
of the target protein across the groups by normalizing the intensity of the beta actin with the 
bands' intensity of target protein in each sample.  
Methodological rigor and data analyses  
All animals were randomized and coded with numbers before treatment protocols. The 
analyzers were not informed about the genotype of the mice until the data analyses were 
accomplished. The dead mice during 20 minutes-seizure recording were excluded from the 
study. Statistical analyses were performed in Prism 4.0 (GraphPad Software), and normality of 
each dataset was evaluated. Normal datasets were analyzed using one-way ANOVA with Tukey-
Kramer post hoc test to compare maximum seizure score, latency, skeleton analysis of microglia 
and protein expression in IHC and Western blotting between genotypes. Two-way ANOVA was 
used to compare seizures severity in all experimental groups. In the co-localization of AT8 and 
Fyn experiment, a pairwise comparison between two groups was made using the nonparametric 
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Mann-Whitney test. The differences with p-value < 0.05 were considered significant. All values 
are shown as mean standard error of the mean. 
Results 
Fyn and tau ablation suppresses the severity of behavioral seizures after PTZ injection 
The neuroprotective mechanisms of tau ablation against behavioral seizure had been 
shown in the chemoconvulsant-induced seizure animal models such as PTZ (7,9,19), kainic acid 
(19,20), and even in the genetic models of epilepsy (6,18). In contrast, the anti-convulsive 
property of Fyn reduction is still controversial (28). Therefore, as the first step of re-evaluating 
the neuroprotective effects of Fyn-/-, Tau-/-, double mutant Fyn-/-+ Tau-/- against acute seizure 
activity, we performed video behavioral seizure recording analysis. After injected 
intraperitoneally with PTZ, seizure severity was scored over subsequent 20 min period. On the 
wild-type (WT) background, mice reached convulsive seizure stage in the first 2 min after PTZ 
injection, which was earlier than the other mice group (Fig 2A). Compared with WT mice, Fyn-/- 
mice showed a mild but significant reduction in stereotypic stages of seizure severity, while 
more profound seizure suppression was observed in Tau-/- and double mutant Fyn-/-+ Tau-/- mice 
(Fig 2B). Moreover, Tau-/- and double mutant Fyn-/-+ Tau-/- mice significantly had longer seizure 
latency, whereas Fyn-/- did not significantly differ from WT littermates (Fig 2C). Unexpectedly, 
Fyn-/- mice had a 60% mortality during the 20-minute observation (7 out of 12 mice), which is 
higher than WT counterparts that only showed 40% (5 out of 12 mice) mortality after PTZ 
administration (Fig 2D). None of the other mice group had shown mortality during this 
experiment. Based on the data, Tau-/-  and double mutant Fyn-/-+ Tau-/- suppressed severity of 
seizure better than Fyn-/- alone. Although Fyn-/- mice showed a high incidence of mortality, it is 
evident that Fyn and tau ablation reduces susceptibility to excitotoxic PTZ induced seizures. 
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Hyperphosphorylated tau (AT8 labeling) after 24 h PTZ Injection 
Tau interacts with Fyn through a binding to its SH3 domain while Fyn also 
phosphorylates tau in vitro at specific phospho-epitope of tau, Tyr18 (12). The level of 
hyperphosphorylated tau at Ser202/Thr205 (AT8) increases as early as 10 h in kainic acid-
induced excitotoxic seizure (57). Moreover, it is also evident that the accumulation of tau 
pathology labeled with AT8 marker occurs in 94% post-resected temporal lobe epilepsy cases 
(58). Thus, to test out the interaction between phosphorylated tau and Fyn, we employed double-
immunostaining of Fyn and AT8 (Fig 3A). At 24 h post-PTZ, the results showed that the 
percentage of Fyn-positive cells co-expressing AT8 (arrow indicated) in CA3 region of the 
hippocampus in WT (39%) was significantly increased when compared with the vehicle control 
(7%) (Fig 3B). Likewise, co-expression of Fyn and AT8 in the entorhinal cortex of WT treated 
PTZ (56.88%) were also significantly higher than the vehicle control (8.75%) (Fig 3C). The 
PTZ-induced seizure upregulates the expression of hyperphosphorylated tau in the early period 
of epileptogenesis.    
Fyn and tau loss reduced microgliosis after the PTZ-induced SE 
Microgliosis is one of the epilepsy hallmarks characterized by increased microglial 
immunoreactivity and marked morphological changes of microglia (59,60). Previously, we had 
shown the neuroprotective features of disabling Fyn and tau against seizures. We thus aimed to 
observe the similar effects at the cellular level by examining microglia reactivity at 24 h post-
PTZ. In the PBS-treated mice (vehicle control) for all genotypes, IBA1 positive cells were 
equally dispersed throughout hippocampal regions (CA1 and CA3) featuring thin, long processes 
and small cell somas (Fig 4A). By contrast, the IBA1+ cells with thickened, shortened processes 
and larger cell bodies clustered around the dying pyramidal neurons in the hippocampus of WT 
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treated PTZ. The Fyn-/-, Tau-/-, and double mutant Fyn-/-+ Tau-/- prevent microgliosis after PTZ 
injection as compared with WT (Fig 4A). In CA3, CA1, and DG, WT showed a significant 
increase of immunoreactivity against IBA1 as compared with its naïve control (Fig 4B-D). In 
CA3 specifically, all the KO mice suppressed the numbers of microglia as compared with WT. 
Furthermore, Fyn-/- and double mutant Fyn-/-+ Tau-/- mice showed significant suppressive effects 
towards microgliosis after PTZ injection (Fig 4B). In DG, Tau-/-, double mutant Fyn-/-+ Tau-/- 
mice significantly reduced the number of microglia while Fyn-/- mice showed no difference from 
WT treated with PTZ (Fig 4D). Overall, the combined ablation Fyn and tau reduce microgliosis 
more profoundly than Fyn or tau reduction alone.  
We then quantified microglial morphology in the hippocampus using skeleton analysis 
(55,56) to identify morphological shift of microglia during the early phase of epileptogenesis. 
Representative images with a focus on a single cell in each experimental group were captured 
and converted to skeletonized images (Fig 5A). The cell body area, the number of endpoints 
representing branch quantity and the longest processes path corresponding to an area of influence 
were acquired as described in Methods section. All genotype controls treated with PBS showed 
small cell body area, and thin and long processes extending away from the soma with a high 
value of the number of endpoints and the longest processes path (Fig 5A, arrows indicated). In 
contrast, WT had larger cell body area as well as short processes indicated by a significantly 
lower value of the number of endpoints and the longest processes path as compared to vehicle 
control (Fig 4B, C, D). Double mutant Fyn-/-+ Tau-/- mice significantly resolved microglial cell 
body size by reduction to 26.97% following 42.39% increase in WT after PTZ, while others KO 
mice showed mild reduction but not significant of microglial soma size (Fig 4B). Fyn-/- and 
double mutant Fyn-/-+ Tau-/- background significantly recovered the length of microglial longest 
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processes path by 30.14% and 30.97%, respectively while Tau-/- background had no significant 
effect (Fig 4C). Likewise, double mutant Fyn-/-+ Tau-/- mice displayed the greatest improvement 
(98%) microglia process endpoints followed by Tau-/- (55.36%) mice but not Fyn-/- mice when 
compared with WT post-PTZ (Fig 4D). Disabling both Fyn and tau had shifted back ameboid-
like shape of microglia toward the typical ramified morphology. Double mutant Fyn-/-+ Tau-/- 
mice showed the most pronounced anti-inflammatory effects of both Fyn and tau reduction.   
Fyn and tau ablation reduced reactive astrogliosis and prevented downregulation of 
astrocytic Kir 4.1 levels after PTZ-induced SE  
  An enlarged morphology, increased molecular contents and proliferation state of 
astrocytes so-called astrogliosis are prominent in epilepsy (48,49). Moreover, as the disease 
progresses, astrocytes continue to malfunction by perpetuating hyperexcitability in epileptic 
brains (39). We further investigated whether ablating Fyn and tau can mitigate astrogliosis post-
PTZ as this is what we had observed in microgliosis. We observed morphological changes such 
as hypertrophic cell bodies and processes as well as increase number of processes in WT after 
PTZ (Fig 6A). As early as 24 h post-PTZ, we found a significant increase of GFAP+ cells in 
CA1, CA3 regions of the hippocampus, DG in WT background (Fig 6A, B). It was only the 
double mutant Fyn-/-+ Tau-/- mice that significantly reduced the number of GFAP+ cell in CA1 
and CA3 while others KO showed a similar pattern of reduced astrogliosis but not significantly 
different from WT (Fig 6B). In DG, however, all KO mice significantly attenuated astrogliosis 
when compared with WT (Fig 6B).   
 We then assessed one of the astrocyte functions as a major regulator of K+ homeostasis 
by analyzing expression of inwardly rectifying K+ channel (Kir 4.1). This channel is markedly 
reduced in experimental models of epilepsy and human epilepsy (43,61–63). Hence, it leads to a 
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compromised spatial K+ buffering which is highly correlated with epilepsy phenotype (37). We 
performed immunohistochemistry to observe expression of Kir 4.1 in astrocytes (Fig 7A). The 
representative images showed the downregulation of astrocytic Kir 4.1 in DG of WT post-PTZ 
as compared to control whereas all KO mice prevented the loss of Kir 4.1 against PTZ-induced 
seizure (Fig 7A). To further confirm our observation, we conducted hippocampal western blot 
(7B). As expected, we encountered similar finding where expression of Kir 4.1 was indeed 
significantly decreased in WT while all KO mice retained its level at 24 h post-PTZ (Fig 7C). 
Overall, these findings support our hypothesis that ablating Fyn and tau ameliorates astrogliosis 
and restores astrocytic Kir 4.1 expression in the early period of epileptogenesis.    
Ablating Fyn and Tau protected against neurodegeneration and loss of interneurons 
induced by PTZ 
Neuronal degeneration in pyramidal cells occurs as soon as 24 h after sustained seizures 
in animal models (64). Moreover, the apparent loss of specific population of GABAergic 
interneurons has been associated with aberrant excitation in epilepsy mice model (65). As Fyn 
and tau interaction induces neurodegeneration in AD (7,32), we further investigate whether 
disabling Fyn and tau might ameliorate neurodegeneration induced by PTZ. By coupling Neun 
and FJB marker to label dying neurons (Fig 8A), we found significantly increased 
neurodegeneration after PTZ injection in CA3, CA1, DG of WT mice (Fig 8B). The number of 
FJB positive neurons values was significantly reduced in those regions (> 50%) in all KO mice 
when compared with WT.  
We then examined the detrimental effect of Fyn and tau on the specific major interneuron 
subtype that expresses parvalbumin (Fig 9A). The number of PV-expressing interneurons in CA3 
(58.76%) and CA1 (52.61%) regions was significantly reduced in WT post-PTZ when compared 
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to vehicle control (Fig 9A, B). In DG, no difference of PV+ cell numbers in all groups was 
observed compared with their controls after PTZ administration (Fig 9B). All KO mice 
significantly increased the number of PV+ cells in all subfields of the hippocampus as compared 
with WT after PTZ injection (Fig 9A-C). Surprisingly, in CA1, double mutant Fyn-/-+ Tau-/- mice 
showed a slight increase but not significant immunoreactivity against PV as compared with its 
controls (Fig 9B). We further moved forward to specifically observe a similar loss in the 
entorhinal cortex where the major excitatory inputs to DG originate (Fig 8A). We found a 
reduction of PV+ cells in WT () while only Tau-/- and double mutant Fyn-/-+ Tau-/- mice showed 
a significant increase of PV-expressing interneurons as compared to WT post-PTZ (Fig 8A, E). 
Thus, blocking Fyn and tau expression subdues neurodegeneration and loss of Parvalbumin 
interneurons in the early epileptogenesis.  
Discussion 
Tau loss abolishes neuro-excitotoxicity resulting in resistance to seizure induction 
(7,9,19) while Fyn reduction reduces SE-induced mortality (22), phosphorylation of tau and 
suppressed inflammation in AD mouse models (24). Also, phenotypes of genetic epilepsy are 
resolved by complete tau ablation (6,18). It is then imperative to characterize the effects of Fyn 
and tau reduction in acute seizures induction, therefore providing insights for early intervention 
approach. Our study demonstrates the neuroprotective phenotypes of Fyn and tau reduction 
against PTZ induced seizures in the early phase of epileptogenesis, as PTZ resistant compounds 
are more likely to undergo successful clinical trial (66). Crossed Fyn-/- and Tau-/- mice showed 
reduced seizure severity, increased latency to convulsive seizures (Fig 2). While tau KO mice 
had similarity to the double mutant mice, the Fyn KO mice only exerted mild anti-seizure 
effects, but with high mortality rate. Similarly, Chin et al. (22) reported higher death incidence of 
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Fyn-deficient mice in the absence of the human amyloid precursor protein (hAPP) gene mutation 
whereas the opposite observation reported when crossing with hAPP transgenic mice. Moreover, 
a morphological brain abnormality like hydrocephalus (67,68) was prominently observed in our 
Fyn-/-  mice that might contribute to the increased mortality rate in this study (data not shown). It 
is worth noting that the Fyn-/- mice used in this study were bred on the S129 x C57BL/6J genetic 
background. In the single tau KO mice, there was an increased survival rate against chronic 
seizures of genetic epilepsy (6,18) and neurotoxicity in AD models (7,19,20). Although double 
mutant Fyn-/-+ Tau-/- mice also exhibited a lower incidence of hydrocephalus, concomitant tau 
ablation might counteract the off-target effects of Fyn reduction resulting in a rather pronounced 
protective effect. Hitherto, there are no reports about seizure-induced death in Fyn-deficient 
mice. There have been conflicting results emerging from studies that showed the vulnerability of 
Fyn-deficient mice to develop seizures (29,30) while others found that Fyn removal increased 
seizure threshold (16,28,69). Moreover, coupling overexpression of Fyn and APP increases 
mortality after PTZ administration. Perhaps, the difference of mice genetic background could 
influence the response to chemoconvulsants in epilepsy mouse model, and contribute to the 
contradictory findings reported in the literature (70). Despite disputable Fyn roles in 
epileptogenesis, our data are consistent with the evidence that tau removal is neuroprotective 
against PTZ induced seizures (5,7) and Fyn and tau complex modulates the severity of seizures 
in the early epileptogenesis. Furthermore, an ablating synergy of both proteins showed more 
noticeable protective effects indicating the seizures activity-dependent of Fyn-tau interaction. 
At the synaptic level, the phosphorylated tau serves as a chaperone to localize Fyn in the 
post-synaptic terminal (7,12). Fyn then phosphorylates NR2B subunit of NMDAR at Tyr 1472 
facilitating the interaction of PSD-95 and NR2B (70,71) to stabilize the NR2B/PSD-95/tau/Fyn 
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complex (31). As a result, NMDAR is activated, allowing overload of Ca2+ and Na+ into the 
neurons that lead to hyperexcitability and neurodegeneration (7,31,32). In the KA-induced 
seizures, the upregulation of multiple tau phospho-epitopes, up to 3-4 fold, including Ser 202 and 
Thr 205 (AT8) was observed within 10 hours after the insult. Indeed, the interaction between 
Fyn and tau is enhanced after hyperphosphorylation of tau at AT8 sites (11,72). Consistent with 
those reports, we observed increased co-expression of AT8 and Fyn as early as 24 h in PTZ 
model (Fig 3). Therefore, hyperexcitability mediated neurodegeneration observed in our model 
could be due to neurotoxic hyperphosphorylated tau. A recent study, however, showed early 
hyperphosphorylation of tau at Thr205 diminishes the severity of seizures through dissociation of 
NR2B/PSD-95/tau/Fyn complexes (73), which is opposite to our finding. Additionally, an earlier 
study reported a similar result that tau phosphorylation prevents excitotoxicity driven by 
NMDAR activation (72). Since tau can be phosphorylated at 80 residues, approximately half of 
those residues have been reported to be abnormally phosphorylated in AD models (74). As one 
study reported, seizures associated with increased phosphorylation of tau at Ser 202 (75). We 
then reasoned that the other phospho-epitope of AT8, at Ser 202, could have detrimental effects 
that we observed in our wildtype PTZ model. Further confirmation through different approaches 
for this study is required to understand the mechanisms and discrepancy of the results.   
SE causes reactive gliosis characterized by increased the GFAP content, hypertrophy, 
increased number of processes in astrocytes, and morphological changes. Similar to astrocytes, 
microglia also undergo changes in morphology following seizure such as enlarged cell bodies, 
retracted processes, and an increase in number and migration (36,60,76). Expression of Fyn and 
tau were not only confined in the neurons but also at low abundance present in microglia 
(25,77,78) and astrocytes (26,79). Previously, several studies reported Fyn enhances 
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inflammatory milieu in PD (25) and AD models (24) leading to progression of the disease. 
Moreover, the expression of fyn mRNA is upregulated in the reactive astrocytes and neurons 
after seizures (26). There are some evidence showing that expression of hyperphosphorylated tau 
induces reactive microglia in vitro (80). Little is known, however, about the roles of Fyn and tau 
in regulating inflammatory state following insults. In the present study, we showed the most 
conspicuous suppression of astrogliosis and microgliosis displayed by double mutant Fyn-/-+ 
Tau-/- mice (Fig 4 and Fig 6). Additionally, we observed the restoration of microglial 
morphology, similar to the surveillant and ramified state, in the Fyn and tau KO mice, while 
amoeboid-like microglia was observed in the WT following PTZ administration (Fig 5). On the 
other hand, the Kir 4.1 levels reflecting the K+ buffering function of astrocytes, was retained in 
reduced Fyn and tau mice (Fig 7) after PTZ injection. This specific channel has been evidently 
downregulated in acute seizures (63) as well as in chronic epileptic human brain (61,62); 
however, the mechanism of how Fyn/tau complex influence astrocytic Kir 4.1 level remains 
elusive. Nevertheless, our study suggests that neuroprotective effects against hyperexcitability of 
Fyn and tau ablation are not only achieved through disruption of NR2B/PSD-95/tau/Fyn 
complexes in the neurons but also through modulation of the inflammatory state in both 
astrocytes and microglia during the early phase of epileptogenesis. 
Fyn-/-, Tau-/-, and double mutant Fyn-/-+ Tau-/- mice were protected from hippocampal 
neurodegeneration (Fig 8) as extensive studies have shown that neurodegeneration is one of the 
early epileptogenic hallmarks (48,64,81). This finding is consistent with the conceived 
mechanism of Fyn/tau complex induced neurodegeneration by Ittner (7,32,73). Another 
noteworthy finding is that the loss of PV-interneurons was rescued by Fyn and tau loss in the 
entorhinal cortex and the CA3, CA1 region of the hippocampus (Fig 9). Surprisingly, no changes 
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ensued after PTZ administration in DG indicating possible contribution of continuous 
neurogenesis in subgranular layer of DG (Fig 9B) (82). While phosphorylated tau diminishes the 
number of PV-interneurons (83), the reduction of his subtype of interneurons has been observed 
in the pathogenesis of epilepsy (65,84). Even though the roles of Fyn is not well understood in 
the loss of interneurons after PTZ, the capacity of Fyn to phosphorylate tau (13) might indirectly 
contribute to the loss of PV interneurons. 
In summary, we reveal the beneficial effects of Fyn and tau reduction at the behavioral 
and cellular level. It is evident that reducing both Fyn and tau exerts more pronounced effects 
compared with Fyn or tau ablation alone. Accordingly, the formation of Fyn and tau complex 
appears to be pivotal in facilitating disease progress in the early phase of epileptogenesis. It is, 
however, not well understood how PTZ causes hyperphosphorylation of tau in the first place and 
whether PTZ also utilizes other mechanisms apart from Fyn and tau to induce gliosis and 
neurodegeneration. Further studies should be thus addressed at delineating the key signaling 
pathways of those mechanisms. Overall, this study highlights the possibility of targeting tau and 
Fyn at the early stage of epileptogenesis.   
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Figures and Legends 
 
Figure 1. The experimental design and genotype validation.   
A) Timeline showing the experimental design. Behavioral seizures analysis was conducted for 
20 min after PTZ injection. All mice were sacrificed at 24h post PTZ for immunohistochemistry 
and Western blot.  
B) The Western Blot confirmation for mice genotypes. Normal protein levels of Fyn and tau are 
shown in WT mice, while these proteins were absent in double mutant Fyn-/-+Tau-/- mice. No 
expression of Fyn was found in Fyn-/- mice, while the total tau protein was preserved. No 
expression of total tau was detected in the Tau-/- mice while the fyn protein was preserved. The 
beta actin confirmed equal loading of the samples.    
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Figure 2. Behavioral Seizures Analysis.   
A) Time course of behavioral SE during initial 20 minutes following PTZ administration. Fyn-/-, 
Tau-/- , double knockout Fyn-/-;Tau-/- mice were less susceptible to CS (Racine score < 3) 
compared with WT (n=7-10 per group; ***P<0.001,*P<0.05; F(3,563)=48.65; two-way 
ANOVA with Bonferroni’s multiple posthoc test).   
B) The maximum seizure severity was significantly reduced in double KO Fyn-/-+Tau-/- and Tau-
/- mice reduced. The Fyn-/- mice showed only mild but significant decline of seizure severity 
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stage (n=7-10; ***P<0.001,*P<0.05; F(3,32)=35.32; one-way ANOVA with Tukey’s multiple 
posthoc tests).  
 C) Latency to the onset of CS (Racine score ≥  3) was significantly increased in double KO Fyn-
/-+Tau-/- and Tau-/- mice. The Fyn-/- mice showed a tendency to increased seizures latency, but 
was not significant since the morality occurred in <20min of PTZ administration in the vast 
majority of these mice (n=7-10; ***P<0.001, ns, not significant; F(3,36)=8.693; one-way 
ANOVA with Tukey’s multiple posthoc test).  
D) The Fyn-/- mice had a greater percentage of seizure associated mortality than WT. And the 
mortality occurred <20 min post-PTZ. 
Data presented as a mean ± standard error of mean (SEM). 
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Figure 3. Increased expression of AT8 after seizures in the WT mice in both the 
hippocampus and entorhinal cortex.   
A) Double immunostaining of AT8 and fyn in WT mice at 24h post-PTZ showing the significant 
increase of AT8+Fyn double positive cells in the CA3 subfield of the hippocampus and 
entorhinal cortex. Arrows indicate co-localization of AT8 with Fyn in the cells. Scale bar, 50 
µm. 
B) Percentages of AT8/Fyn double-positive cells in CA3 of the hippocampus and entorhinal 
cortex (ENT) (n=3-4; *P<0.05; Mann-Whitney test). Data presented as a mean ± standard error 
of mean (SEM). 
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Figure 4. Reduced microgliosis in the Fyn and tau KO mice following seizure induction.   
A) The hippocampus of indicated groups was labeled with IBA1 and imaged with an x10 
objective. Scale bar, 100 µm. Magnified images of the different morphology of microglia with 
x40 are shown (right). Scale bar, 10 µm. 
B) Microglial cell quantification. At 24h post-PTZ, the number of microglia significantly 
increased in wild type group as compared with control in the hippocampus. All KO mice 
suppressed microgliosis in CA3 subfield (F(7,26)=16.25).  In CA1 subfield, only Fyn-/- and 
double knockout Fyn-/-;Tau-/- mice significantly attenuated microgliosis while Tau-/- mice 
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showed significant increase in microglial number  (F(7,26)=18.34). In DG region, only Tau-/-, 
double knockout Fyn-/-;Tau-/- mice had a suppressive effect toward microgliosis while Fyn-/- mice 
did not display similar effect (n=4-6; ***P<0.001, **P<0.01, *P<0.05, ns, not significant; 
F(7,25)=9.826; one-way ANOVA with Tukey’s multiple posthoc test). The total number of 
IBA1 cells was counted from a predetermined area. Data presented as a mean ± standard error of 
mean (SEM). 
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Figure 5. Fyn and tau loss restored polarization of microglia after seizures.   
A) Images show IBA1 positive cells at 24h post-seizures captured with x40 objective. The cell 
body was measured as shown (yellow-colored areas). Scale bar 10 µm. Skeletonized images 
were obtained to quantify the processes of microglia. The number of endpoints (arrows 
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indicated) and two longest processes path (red processes) per microglia were quantified for 
statistical comparison across the groups. Scale bar 10 µm. 
B) Cell body area was increased in the WT and significantly reduced in only double knockout 
Fyn-/-+Tau-/- mice (n=4-6; *P<0.05, ns, not significant; F(7,26)=4.734; one-way ANOVA with 
Tukey’s multiple posthoc test).  
C) PTZ induced seizures reduced summed length of two microglial longest processes in WT 
while Fyn-/- and double knockout Fyn-/-+Tau-/- mice had no impact of PTZ on microglial 
morphology (n=4-6; ***P<0.001, **P<0.01, *P<0.05, ns, not significant; F(7,26)= 11.76; one-
way ANOVA with Tukey’s multiple posthoc test).  
D) Reduced number of microglial endpoints was observed following PTZ administration in the 
WT.  All knockout mice except Fyn-/- mice significantly recovered the endpoints number as 
compared with WT (n=4-6; ***P<0.001, *P<0.05, ns, not significant; F(7,26)= 7.612; one-way 
ANOVA with Tukey’s multiple posthoc test). Data presented as a mean ± standard error of mean 
(SEM). 
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Figure 6. Reduction of Fyn and tau suppressed astrogliosis following seizure induction 
A) Representative x10 images of all groups labeled with GFAP after PTZ injection. Scale bar, 
100 µm. Enlarged images captured with x40 objective are shown to contrast morphology of 
astrocytes at 24 h following PTZ injection right. Scale bar, 10 µm. 
B) Astrocyte cell quantification. Following 24 h post-PTZ, the numbers of GFAP positive cells 
were significantly increased in the wild type group compared with the naïve control (vehicle) in 
the hippocampus. Double knockout Fyn-/-+Tau-/- mice showed significant reduction of 
astrogliosis in CA3 (n=4-6, F(7,23)=6.98) and CA1 (n=4-6, F(7,23)=7.348) subfields while 
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others did not. In DG, all KO mice suppressed astrogliosis significantly (n=4-6; ***P<0.001, 
**P<0.01; F(7,26)= 15.35; one-way ANOVA with Tukey’s multiple posthoc test). Data 
presented as a mean ± standard error of mean (SEM). 
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Figure 7. Expression of Kir 4.1 at 24h after seizure induction.   
A) Immunohistochemistry images show co-localization of Kir4.1 with GFAP in DG across all 
experimental groups (arrows indicated). Scale bar, 100 µm. Representative enhanced images of 
double labeled astrocytes. Scale bar, 20 µm. 
B) Western blotting of hippocampal brain extract show reduced expression of Kir 4.1 following 
PTZ injection. In contrast, All KO successfully retained the level of Kir 4.1 after seizures.  
C) Quantified WB results of all groups are shown (n=4; **P<0.01, *P<0.05; F(7,24)= 5.123; 
one-way ANOVA with Tukey’s multiple posthoc test). Data presented as a mean ± standard 
error of mean (SEM). 
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Figure 8. Neurodegeneration was significantly reduced in effects of Fyn and Tau KO mice.   
A) Fluoro-Jade B staining coupled with neuronal marker Neun in hippocampal tissue sections at 
24 h after seizures shows more dying neurons in WT compared with all KO littermates. Scale bar 
100 µm. Enhanced degenerating regions of CA1 captured with x20 objectives are shown (right). 
Scale bar 100 µm. 
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B) A plot of the number of FJB positive neurons in CA3 (F(7,24)=23.17), CA1 (F(7,24)=15.08), 
and DG (F(7,24)=56.34). All KO mice significantly reduced neurodegeneration following PTZ 
administration (n=4; ***P<0.001; one-way ANOVA with Tukey’s multiple post hoc test). Data 
presented as mean ± a standard error of mean (SEM). 
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Figure 9. Loss of parvalbumin expressing interneurons was rescued in Fyn and Tau KO 
mice after seizures.   
A) Parvalbumin (PV) immunoreactivity is shown in all experimental groups in CA3 and 
entorhinal cortex. PV interneurons labeled are reduced in CA3 and the entorhinal cortex. Scale 
bar, 100 µm.  
B) Quantification of PV-expressing cells in the hippocampus and entorhinal cortex. The numbers 
of PV interneurons were not reduced in any of the KO mice in the CA3 (F(7,24)=8.903)  and 
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CA1  (F(7,18)=5.216). The Tau-/- mice and double knockout Fyn-/-+Tau-/- mice showed a 
significant increase of PV numbers in the entorhinal cortex (F(7,24)=4.0234), while in the Fyn-/- 
mice there was a marginal effect. No changes were observed in the DG (F(7,23)=0.5109) across 
all experimental groups following PTZ injection. (n=4-6; ***P<0.001**P<0.01, *P<0.05, ns, not 
significant; one-way ANOVA with Tukey’s multiple posthoc test). Data presented as a mean ± 
standard error of mean (SEM). 
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CHAPTER 3: GENERAL CONCLUSIONS 
 
Summary and future directions 
The study presented in this thesis aids in elucidating the roles of the Fyn and tau complex 
in the early phase of epileptogenesis. With respect to the hallmarks of early epileptogenic events 
such as neurodegeneration and neuroinflammation, we would like to analyze the contributions of 
Fyn and tau on those markers of epilepsy by knocking out corresponding proteins. Studies have 
shown the therapeutic potential of agents that reduce Fyn and tau levels in several models of 
neurodegenerative disorders (1–7). This thesis provides additional information on the role of Fyn 
and tau in neuroinflammation and neurodegeneration in the PTZ model of epilepsy. This study 
shows potential modulation of the inflammatory state is driven by astrocytes and microglia in the 
early stages of epileptogenesis through reduction of Fyn and tau. Additionally, an inevitable loss 
of inhibitory interneuron population was also observed in our model in as early as 24 h, while 
some studies showed similar damage occurring at 72 h post insults. Further research is required 
to understand the mechanism by which the loss of GABAergic interneurons was prevented in 
knockout mice of tau and Fyn.  
Our study extrapolates the roles of Fyn and tau beyond neuro-excitotoxicity to include 
the engagement of resident glial cells and GABAergic interneurons in the early epileptogenic 
events. Additionally, mounting evidence pointed out their roles in enhancing inflammation 
(4,8,9) and neurodegeneration (10) following insults. These roles, however, have not been fully 
explored in the model of early epileptogenesis. Therefore, our study provides insight on how the 
reduction of Fyn and tau may help elucidate the cellular changes in the brain following PTZ 
administration and their association with the anti-seizure phenotypes observed.      
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The long-term effects of complete loss of Fyn and tau have not yet been evaluated 
thoroughly. Potential adverse effects of early Fyn and tau ablation are evident in our study, and 
have been shown in other studies, as they are crucial for neurodevelopment of the brain. As 
previously described, tau loss does not show any adverse effects in aged mice, and maintains its 
anti-seizure property (11), while another study showed Parkinson-like behavior with Tau 
deficiency (12). Therefore, survival rate, the incidence of brain defects, behavioral changes, and 
spontaneous recurrent seizures of all three mutants need to be thoroughly examined and reported 
as the strain of mouse used could vary the results.  In the present study, electrographic recordings 
of spontaneous recurrent seizures after PTZ administration were not obtained. This analysis is 
pivotal to determine the propensity of each mice group towards the development of epilepsy. 
It is not yet understood how the PTZ induced SE phosphorylates tau and which kinases 
are involved, in addition to the role of Fyn in facilitating the process. Possible kinases such as 
cdk5, GSK-3β, and CK1 have been attributed to the hyperphosphorylation of tau in 
neurodegenerative diseases (13,14). Also, the expression of cdk5 and GSK3β are upregulated 
followed by increased phosphorylation of tau in the KA induce seizure model (15), therefore 
blocking these kinases could be potentially beneficial for therapeutic intervention.  
Future studies also need to address the tau-dependent mechanisms of targeting PSD-95 or 
NMDR receptor to evaluate whether such interventions will exert the same effects as seen in our 
model of Fyn and tau ablation. Perturbing the NMDAR, dissociates the complex of PSD-
95/NR2B thereby inhibiting Fyn and tau-mediated excitotoxicity in AD model (10). 
Theoretically, these approaches could yield similar effects. Moreover, studies also should be 
conducted in different animal models of epilepsy. If successful, it may facilitate our 
understanding of the involvement of NR2B/PSD-95/Fyn/tau complexes in epilepsy. Thus, more 
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research on this subject may broaden our knowledge on the efficacy of targeting these complexes 
for the therapeutic intervention of epilepsy, which may be attributable to patients with intractable 
epilepsy.  
This study could be further explored to characterize the profile of microglia and astrocyte 
reactivity as well as the mechanisms of Ca2+ induced neurodegeneration during epileptogenesis. 
Analysis of anti- and proinflammatory profiling displayed by microglia and astrocytes will 
redefine the roles of Fyn and tau. Overall, our study reveals the significant roles of Fyn and tau 
in the variant and deleterious aspects of epileptogenesis, which may lead to better understanding 
the development of epilepsy.   
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